Table 3. Joinpoint regression of the evolution of the age- and sex-standardised prevalence rate of polypharmacy (≥5 drugs) between 2000 and 2015.
| Group | SR in 2000–2015 (%) | Summary AAPC | Trend 1 | Trend 2 | Trend 3 | |||
|---|---|---|---|---|---|---|---|---|
| Years | APC (95%CI) | Years | APC (95%CI) | Years | APC (95%CI) | |||
| Total | 18.0–25.2 | 2.0 (1.6; 2.4)** | ||||||
| Females | 20.5–28.9 | 1.9 (1.4; 2.3)** | ||||||
| <25 years | 12.0–11.3 | -0.3 (-0.9; 0.3) | ||||||
| 25–49 years | 16.5–23.5 | 1.9 (1.4; 2.5)** | ||||||
| 50–74 years | 294–41.8 | 1.8 (1.4; 2.3)** | ||||||
| ≥75 years | 28.4–51.0 | 3.5 (3.0; 4.0)** | 2000–2009 | 4.6 (4.0; 5.2)** | 2009–2013 | 0.3 (-2.7; 3.4) | 2013–2015 | 8.3 (1.9; 15.2)** |
| Males | 15.4–21.5 | 2.1 (1.7; 2.6)** | ||||||
| <25 years | 9.8–8.2 | -1.3 (-2.0; -0.6)** | ||||||
| 25–49 years | 10.2–13.7 | 1.6 (1.0; 2.1)** | ||||||
| 50–74 years | 23.0–34.5 | 2.7 (2.2; 3.3)** | 2000–2009 | 4.0 (3.2; 4.8)** | 2009–2015 | 0.5 (-0.9; 1.9) | ||
| ≥75 years | 27.8–52.4 | 4.2 (3.7; 4.6)** | ||||||
** p<0.05
SR: age- and sex-standardised prevalence rate; AAPC: Average annual percent change; APC: annual percent change; 95%CI: 95% confidence interval